NEK6 and ovarian carcinoma: Another study by De Donato et al. (2018) found a compound named compound 8, that binds to NEK6 and NEK1 kinase domains and inhibits their kinase activities, increasing cisplatin sensibility in PEO1 cells, another ovarian cancer cell line [158].